Table 2.

Summary of engraftment, HSCT complications and outcomes.

Patient	Days to ANC>500/mm3	Days to plts>20,000/mm3	Acute GVHD	Chronic GVHD	Other toxicity	DLI	Second generation TKI use post HSCT	Current status	F/U
1	12	9	No	Yes	No	No	NiIotinib commenced at day +38 for 2weeks. Stopped due to cytopenias. Recommenced at+4 months and stopped at +7 months owing to recurrent cytopenias despite GCSF	CMR	54 Months
2	9	9	No	No	Likely CMV pneumonitis	No	Dasatinib commenced day +50. Stopped after 2 weeks owing to GI side effects.	MMR	44 Months
3	17	8	No	No	PTLDc	Yes Total dose: 0.52×107/kg	1. Dasatinib started day+86, stopped after 6 weeks owing to cytopenias	MMR	53 Months
							2. Nilotinib then used for 4 months but stopped due to cytopenias despite GCSF
4	11	11	No	Yes	Idiopathic thrombocytopenic purpura	Yes Total dose: 6.81×107/kg	Nilotinib started at day+88 but stopped after 4 weeks owing to cytopenias despite GCSF	CMR	51 Months
5	18	a	No	No	Seizures	Yes Total dose: 0.6×1 07/kg	Nilotinib started at day +74, stopped after 3 months owing to deranged LFTs	CMR	46 Months
6b	1.14 2.77	a	1. No 2. Yesb	1. No 2. Yesb	No	No	Dasatinib started day +56 for 5 months and stopped owing to secondary graft failure	Died	21 Months
7	14	12	No	No	No	No	Nil (poor compliance) with previous TKIs	CMR	82 Months
8	11	16	No	No	No	No	Nil (relapsed blast crises)	Diedd	6 Months
9	19	11	Yes	Yes	PTLDc	No	Bosutinib started day+84, remains on at +8 months but poor compliance	Relapsede	13 Months

Abbreviations: ANC is absolute neutrophil count, GVHD is graft versus host disease, DLI is donor lymphocyte infusion, TKI is tyrosine kinase inhibitor, HSCT is haematopoietic stem cell transplant, GI is gastrointestinal, CMV is cytomegalovirus, PTLD is post transplant lymphoproliferative disorder, LFTs is liver function tests, MMR is major molecular response and CMR is complete molecular response.

^aPatients on LMWT heparin – thus platelet count maintained >40 with transfusion throughout cytopenic phase.

^bThis patient received 2 times HSCT owing to secondary graft failure of initial HSCT.

^cBoth patients with PTLD responded to single agent rituximab.

^dRelapsed blast crisis 3 months post HSCT (patient transplanted post second blast crisis in 3rd responsive phase).

^eCytogenetic relapsed likely secondary to poor compliance with post-HSCT TKIs, initial molecular relapse unable to be controlled with DLI owing to concurrent GVHD.